Literature DB >> 494588

The prevalence of hepatitis B surface antigen and its antibody in blood donors and high risk groups in Iran.

H Farzadegan, C Harbour, F Ala.   

Abstract

The prevalence of HBsAg and anti-HBs among voluntary blood donors, professional blood donors, INBTS laboratory staff, haemophiliacs and the patients and medical personnel of three haemodialysis centres was compared. The 3.4% incidence of HBsAg found among 168,890 voluntary donors was significantly less than the 8.4% found among 378 professional blood donors. The prevalence of HBsAg was higher in male than in female donors, and also higher in single than in married donors. Prevalence of HBsAg was unrelated to ABO-Rh blood group but was related to age. Anti-HBs was found in 30% of voluntary blood donors, 67% of professional donors, 68% of haemodialysis patients, 39% of haemodialysis staff, 86% of haemophiliacs and in only 4.8% of HBsAg carriers. Subtyping of HBsAg found in 100 voluntary donors showed 65 were ay; 5 ad; 10 ad + ay and 20 were untypable.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 494588     DOI: 10.1111/j.1423-0410.1979.tb02289.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  20 in total

1.  Frequency of HIV and HCV Co-Infections in Chronic HBV Patients Referred to Taleghani Hospital, Tehran, Iran from 2006 to 2010.

Authors:  Seyed Mohammad Ebrahim Tahaei; Seyed Reza Mohebbi; Pedram Azimzadeh; Mohsen Vahedi; Shohreh Almasi; Sara Romani; Afsaneh Sharifian; Faramarz Derakhshan; Mohammad Reza Zali
Journal:  Hepat Mon       Date:  2011-12-20       Impact factor: 0.660

2.  Study of hepatitis B prevalence in parallel with the most frequent HBV genotype in South Iranian blood donors.

Authors:  Mojgan Noroozi Karimabad; Gholamhossein Hassanshahi; Ahmad Gharebaghiyan; Zohre Sharifi
Journal:  J Clin Lab Anal       Date:  2012-11       Impact factor: 2.352

3.  Intrafamilial spread of hepatitis B virus in Guilan Province-North of Iran.

Authors:  Fariborz Mansour-Ghanaei; Farahnaz Joukar; Maryam Yaseri; Fatemeh Soati; Zahra Atrkar-Roushan
Journal:  Int J Mol Epidemiol Genet       Date:  2013-11-28

4.  A study on delta virus infection and its clinical impact in Iran.

Authors:  H Rezvan; B Forouzandeh; S Taroyan; S Fadaiee; F Azordegan
Journal:  Infection       Date:  1990 Jan-Feb       Impact factor: 3.553

5.  Viral hepatitis induces hepatocellular cancer: what can we learn from epidemiology comparing iran and worldwide findings?

Authors:  Elisabeth Smolle; Evelyn Zöhrer; Kira Bettermann; Johannes Haybaeck
Journal:  Hepat Mon       Date:  2012-10-30       Impact factor: 0.660

6.  Prevalence of chronic hepatitis B infection in Iran: a review article.

Authors:  Jalal Poorolajal; Reza Majdzadeh
Journal:  J Res Med Sci       Date:  2009-07       Impact factor: 1.852

7.  The prevalence of hepatitis B antigen-positivity in the general population of Mashhad, Iran.

Authors:  Farhad Fathimoghaddam; Mohammad Reza Hedayati-Moghaddam; Hamid Reza Bidkhori; Sanaz Ahmadi; Hamid Reza Sima
Journal:  Hepat Mon       Date:  2011-05       Impact factor: 0.660

8.  Occult hepatitis B virus infection: A major concern in HIV-infected patients: Occult HBV in HIV.

Authors:  Amitis Ramezani; Mohammad Banifazl; Minoo Mohraz; Mehrnaz Rasoolinejad; Arezoo Aghakhani
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

9.  Distribution and risk factors of hepatitis B virus infection in the general population of Central Iran.

Authors:  Mohammad Reza Ghadir; Mojtaba Belbasi; Akram Heidari; Mahboobeh Jandagh; Iman Ahmadi; Hosseinali Habibinejad; Alireza Kabiri; Amir Hossein Ghanooni; Abolfazl Iranikhah; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2012-02-29       Impact factor: 0.660

10.  Seroprevalence of hepatitis B surface antigen and anti hepatitis C antibody in zahedan city, iran: a population-based study.

Authors:  Alireza Ansari-Moghaddam; Mohammad Reza Ostovaneh; Batool Sharifi Mood; Esmail Sanei-Moghaddam; Amirhossein Modabbernia; Hossein Poustchi
Journal:  Hepat Mon       Date:  2012-09-30       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.